Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets slip into red
Wed, 17 Apr 01:30 pm

Indian stock markets shed initial gains and fell below the dotted line in the post noon trading session. Among the sectoral indices, stocks from the realty and metal sectors were among the leading gainers, while stocks from the IT and oil and gas sectors were the top losers.

BSE-Sensex is up down by 70 points and NSE-Nifty is trading down by 17 points. While BSE Mid Cap is trading up by 0.2%, BSE Small Cap index is trading up by 0.5%. The rupee is trading at 53.88 to the US dollar.

Majority of the energy stocks are trading in the green with Essar Oil and Jindal Drill leading the gains whereas Reliance Industries and Indraprastha Gas are the major losers. As per a leading financial daily, state-owned Gujarat State Petroleum Corporation (GSPC) will acquire management control of Gujarat Gas in a couple of weeks before its annual general meeting. Reportedly, GSPC has received mandatory clearances from SEBI and Competition Commission of India (CCI) in acquiring a controlling hold over the company. The Gujarat government will appoint four directors on the Gujarat Gas Board. Subsequently, GSPC will be merged with Gujarat Gas to create the country's largest city gas company with over seven lakh customers. The government of Gujarat and GSPC Group are exploring the various options for the integration. GSPC had earlier acquired 73.7% stake in Gujarat Gas for Rs 28.1 bn.

Most of the Indian pharma stocks are trading in the green with Fresenius Kabi and Orchid Chemicals leading the gainers. Ranbaxy Laboratories (RANB), has announced that the company along with its parent company Daiichi Sankyo have launched the hybrid business model in Brazil to expand the business of both the companies. As a part of this synergy, Ranbaxy will support Daichii Sankyo's Brazil subsidiary, by helping the latter to enter the branded generics market. However, Ranbaxy's Brazilian subsidiary viz., Ranbaxy Farmaceutica Ltda would continue to promote Ranbaxy's generics and also enter the branded generics market in Brazil. Reportedly, in Latin America, Brazil is the biggest pharma market and is expected to become the fourth largest in the world by 2016. The stock of Ranbaxy was trading down by 1%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets slip into red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.